Phocas Financial Corp. Reduces Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Phocas Financial Corp. decreased its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 85.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 5,699 shares of the company’s stock after selling 32,190 shares during the period. Phocas Financial Corp.’s holdings in Mirum Pharmaceuticals were worth $236,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Frazier Life Sciences Management L.P. grew its stake in shares of Mirum Pharmaceuticals by 1.2% during the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after acquiring an additional 75,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after purchasing an additional 297,511 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Mirum Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after purchasing an additional 29,017 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $28,913,000. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth about $19,473,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Citigroup lifted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $57.10.

Insider Activity

In other news, CEO Christopher Peetz sold 9,102 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at $5,589,662.40. The trade was a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jolanda Howe sold 1,064 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $51,306.08. Following the completion of the sale, the senior vice president now owns 4,232 shares of the company’s stock, valued at $204,067.04. This trade represents a 20.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,915 shares of company stock worth $1,897,920 over the last three months. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ:MIRM opened at $50.52 on Thursday. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $54.23. The company has a market capitalization of $2.43 billion, a PE ratio of -25.01 and a beta of 0.96. The business has a 50 day moving average of $46.72 and a two-hundred day moving average of $43.32. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The company had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.